Montelukast enhances cytocidal effects of carfilzomib in multiple myeloma by inhibiting mTOR pathway

References

• Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30. doi:10.3322/caac.21387.
   PubMed Web of Science ®Google Scholar
• Michels TC, Petersen KE. Multiple Myeloma: diagnosis and Treatment. Am Fam Physician. 2017;95:373–383.
   PubMed Web of Science ®Google Scholar
• Herndon TM, Deisseroth A, Kaminskas E, Kane RC, Koti KM, Rothmann MD, Habtemariam B, Bullock J, Bray JD, Hawes J, et al. U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res. 2013;19:4559–4563. doi:10.1158/1078-0432.CCR-13-0755.
   PubMed Web of Science ®Google Scholar
• Arastu-Kapur S, Anderl JL, Kraus M, Parlati F, Shenk KD, Lee SJ, Muchamuel T, Bennett MK, Driessen C, Ball AJ, et al. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clin Cancer Res. 2011;17:2734–2743. doi:10.1158/1078-0432.CCR-10-1950.
   PubMed Web of Science ®Google Scholar
• Hajek R, Bryce R, Ro S, Klencke B, Ludwig H. Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM). BMC Cancer. 2012;12:415. doi:10.1186/1471-2407-12-415.
   PubMed Web of Science ®Google Scholar
• Chng WJ, Huang GF, Chung TH, Ng SB, Gonzalez-Paz N, Troska-Price T, Mulligan G, Chesi M, Bergsagel PL, Fonseca R. Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma. Leukemia. 2011;25:1026–1035. doi:10.1038/leu.2011.53.
   PubMed Web of Science ®Google Scholar
• Roy U, Chakravarty G, Honer Zu Bentrup K, Mondal D. Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir. Biol Pharm Bull. 2009;32:2002–2009. doi:10.1248/bpb.32.2002.
   PubMed Web of Science ®Google Scholar
• Savari S, Liu M, Zhang Y, Sime W, Sjolander A. CysLT(1)R antagonists inhibit tumor growth in a xenograft model of colon cancer. PLoS One. 2013;8:e73466. doi:10.1371/journal.pone.0073466.
   PubMed Web of Science ®Google Scholar
• Fonseca BD, Smith EM, Lee VH, MacKintosh C, Proud CG. PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex. J Biol Chem. 2007;282:24514–24524. doi:10.1074/jbc.M704406200.
   PubMed Web of Science ®Google Scholar
• Sancak Y, Thoreen CC, Peterson TR, Lindquist RA, Kang SA, Spooner E, Carr SA, Sabatini DM. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol Cell. 2007;25:903–915. doi:10.1016/j.molcel.2007.03.003.
   PubMed Web of Science ®Google Scholar
• Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol. 2007;9:316–323. doi:10.1038/ncb1547.
   PubMed Web of Science ®Google Scholar
• Fasolo A, Sessa C. mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs. 2008;17:1717–1734. doi:10.1517/13543784.17.11.1717.
   PubMed Web of Science ®Google Scholar
• Maiso P, Liu Y, Morgan B, Azab AK, Ren P, Martin MB, Zhang Y, Liu Y, Sacco A, Ngo H, et al. Defining the role of TORC1/2 in multiple myeloma. Blood. 2011;118:6860–6870. doi:10.1182/blood-2011-03-342394.
   PubMed Web of Science ®Google Scholar
• Chiarini F, Evangelisti C, McCubrey JA, Martelli AM. Current treatment strategies for inhibiting mTOR in cancer. Trends Pharmacol Sci. 2015;36:124–135. doi:10.1016/j.tips.2014.11.004.
   PubMed Web of Science ®Google Scholar
• Tsubaki M, Takeda T, Ogawa N, Sakamoto K, Shimaoka H, Fujita A, Itoh T, Imano M, Ishizaka T, Satou T, et al. Overexpression of survivin via activation of ERK1/2, Akt, and NF-kappaB plays a central role in vincristine resistance in multiple myeloma cells. Leuk Res. 2015;39:445–452. doi:10.1016/j.leukres.2015.01.016.
   PubMed Web of Science ®Google Scholar
• Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L, Sabatini DM. The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science (80-). 2008;320:1496–1501. doi:10.1126/science.1157535.
   PubMed Web of Science ®Google Scholar
• Kim E, Goraksha-Hicks P, Li L, Neufeld TP, Guan KL. Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol. 2008;10:935–945. doi:10.1038/ncb1753.
   PubMed Web of Science ®Google Scholar
• Suraweera A, Munch C, Hanssum A, Bertolotti A. Failure of amino acid homeostasis causes cell death following proteasome inhibition. Mol Cell. 2012;48:242–253. doi:10.1016/j.molcel.2012.08.003.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Nicholatos J, Jr D, Sj R, Sb W, Gs H, Dj K, Bd M. Coordinated regulation of protein synthesis and degradation by mTORC1. Nature. 2014;513:440–443. doi:10.1038/nature13492.
   PubMed Web of Science ®Google Scholar
• Deng C, Lipstein MR, Scotto L, Jirau Serrano XO, Mangone MA, Li S, Vendome J, Hao Y, Xu X, Deng SX, et al. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kdelta and CK1epsilon in hematological malignancies. Blood. 2017;129:88–99. doi:10.1182/blood-2016-08-731240.
   PubMed Web of Science ®Google Scholar
• Xiang RF, Wang Y, Zhang N, Xu WB, Cao Y, Tong J, Li JM, Wu YL, Yan H. MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. Cell Death Dis. 2017;8:e2776. doi:10.1038/cddis.2017.188.
   PubMed Web of Science ®Google Scholar
• Evan GI, Brown L, Whyte M, Harrington E. Apoptosis and the cell cycle. Curr Opin Cell Biol. 1995;7:825–834.
   PubMed Web of Science ®Google Scholar
• Gera JF, Mellinghoff IK, Shi Y, Rettig MB, Tran C, Hsu JH, Sawyers CL, Lichtenstein AK. AKT activity determines sensitivity to mammalian target of rapamycin (mTOR) inhibitors by regulating cyclin D1 and c-myc expression. J Biol Chem. 2004;279:2737–2746. doi:10.1074/jbc.M309999200.
   PubMed Web of Science ®Google Scholar
• Can A, Balci D. Isolation, culture, and characterization of human umbilical cord stroma-derived mesenchymal stem cells. Methods Mol Biol. 2011;698:51–62.
   PubMedGoogle Scholar
• Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149–157. doi:10.1038/leu.2011.196.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Kastritis E, Dimopoulos MA, Lonial S. Treatment options for relapsed and refractory multiple myeloma. Blood. 2015;125:3085–3099. doi:10.1182/blood-2014-11-568923.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Richardson PG, Anderson KC. Promising therapies in multiple myeloma. Blood. 2015;126:300–310. doi:10.1182/blood-2015-03-575365.
   PubMed Web of Science ®Google Scholar
• Avigan D, Rosenblatt J. Current treatment for multiple myeloma. N Engl J Med. 2014;371:961–962. doi:10.1056/NEJMe1407442.
   PubMed Web of Science ®Google Scholar
• Bianchi G, Anderson KC. Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back. CA Cancer J Clin. 2014;64:422–444. doi:10.3322/caac.21252.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27–38. doi:10.1016/S1470-2045(15)00464-7.
   PubMed Web of Science ®Google Scholar
• Zhou M, Gu L, Zhu N, Woods WG, Findley HW. Transfection of a dominant-negative mutant NF-kB inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53. Oncogene. 2003;22:8137–8144. doi:10.1038/sj.onc.1206911.
   PubMed Web of Science ®Google Scholar
• Jacquel A, Colosetti P, Grosso S, Belhacene N, Puissant A, Marchetti S, Breittmayer JP, Auberger P. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition. Oncogene. 2007;26:2445–2458. doi:10.1038/sj.onc.1210034.
   PubMed Web of Science ®Google Scholar
• Holien T, Sundan A. Oncogene addiction to c-MYC in myeloma cells. Oncotarget. 2012;3:739–740. doi:10.18632/oncotarget.631.
   PubMedGoogle Scholar
• Holien T, Vatsveen TK, Hella H, Waage A, Sundan A. Addiction to c-MYC in multiple myeloma. Blood. 2012;120:2450–2453. doi:10.1182/blood-2011-08-371567.
   PubMed Web of Science ®Google Scholar
• Li J, Zhu J, Cao B, Mao X. The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma. Curr Pharm Des. 2014;20:125–135.
   PubMed Web of Science ®Google Scholar
• Gingras AC, Raught B, Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev. 2001;15:807–826. doi:10.1101/gad.887201.
   PubMed Web of Science ®Google Scholar
• Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. 2009;136:731–745. doi:10.1016/j.cell.2009.01.042.
   PubMed Web of Science ®Google Scholar
• Komar AA, Hatzoglou M. Cellular IRES-mediated translation: the war of ITAFs in pathophysiological states. Cell Cycle. 2011;10:229–240. doi:10.4161/cc.10.2.14472.
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Zeldenrust SR, Dingli D, Russell SJ, Lust JA, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–2520. doi:10.1182/blood-2007-10-116129.
   PubMed Web of Science ®Google Scholar
• Cheng H, Leff JA, Amin R, Gertz BJ, De Smet M, Noonan N, Rogers JD, Malbecq W, Meisner D, Somers G. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res. 1996;13:445–448.
   PubMed Web of Science ®Google Scholar
• Zhao JJ, Rogers JD, Holland SD, Larson P, Amin RD, Haesen R, Freeman A, Seiberling M, Merz M, Cheng H. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharm Drug Dispos. 1997;18:769–777. doi:10.1002/(SICI)1099-081X(199712)18:9<769::AID-BDD60>3.0.CO;2-K.
   PubMed Web of Science ®Google Scholar